A new trading day began on Tuesday, with LENZ Therapeutics Inc (NASDAQ: LENZ) stock price down -4.14% from the previous day of trading, before settling in for the closing price of $17.62. LENZ’s price has ranged from $15.70 to $50.40 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -181.63% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -10.98%. With a float of $28.17 million, this company’s outstanding shares have now reached $28.59 million.
In an organization with 42 employees, it is important to assess its efficiency.
LENZ Therapeutics Inc (LENZ) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of LENZ Therapeutics Inc is 9.98%, while institutional ownership is 91.18%. The most recent insider transaction that took place on Nov 17 ’25, was worth 261,022. In this transaction Chief Commercial Officer of this company sold 10,000 shares at a rate of $26.10, taking the stock ownership to the 4,733 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 40,000 for $25.60, making the entire transaction worth $1,024,000.
LENZ Therapeutics Inc (LENZ) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.46 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.93% during the next five years compared to -181.63% drop over the previous five years of trading.
LENZ Therapeutics Inc (NASDAQ: LENZ) Trading Performance Indicators
Here are LENZ Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 12.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -2.82 in one year’s time.
Technical Analysis of LENZ Therapeutics Inc (LENZ)
Let’s dig in a bit further. During the last 5-days, its volume was 0.97 million. That was better than the volume of 0.54 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.58%.
During the past 100 days, LENZ Therapeutics Inc’s (LENZ) raw stochastic average was set at 3.43%, which indicates a significant decrease from 8.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.08 in the past 14 days, which was lower than the 2.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.43, while its 200-day Moving Average is $31.02. However, in the short run, LENZ Therapeutics Inc’s stock first resistance to watch stands at $17.48. Second resistance stands at $18.07. The third major resistance level sits at $18.68. If the price goes on to break the first support level at $16.28, it is likely to go to the next support level at $15.67. Assuming the price breaks the second support level, the third support level stands at $15.08.
LENZ Therapeutics Inc (NASDAQ: LENZ) Key Stats
With a market capitalization of 528.49 million, the company has a total of 31,290K Shares Outstanding. Currently, annual sales are 0 K while annual income is -49,770 K. The company’s previous quarter sales were 12,500 K while its latest quarter income was -16,700 K.
